A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed/Refractory Large B-cell Lymphoma Subjects

• Status: Recruiting
• Trial end date: 2026-02-01

Summary

This is a phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-Tisagenlecleucel (Kymriah®) in subjects with relapsed/refractory large B-cell Lymphoma.

• Phase: Phase 1

Details

• Lead Sponsor: NeoImmuneTech